Status:
COMPLETED
Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever
Lead Sponsor:
University of Oxford
Conditions:
Lassa Fever
Eligibility:
All Genders
10+ years
Brief Summary
Arenaviruses are included in the World Health Organisation R\&D Blueprint list of high priority pathogens, since this virus group includes several epidemic-prone highly pathogenic viruses for which th...
Detailed Description
Summary of cardiovascular function study Lassa fever carries a treated mortality in hospitalized patients of up to 30%. Lassa fever is often described as being characterized by vascular leak and shock...
Eligibility Criteria
Inclusion
- Cardiovascular Study:
- Suspected or RT-PCR confirmed Lassa fever diagnosis
- Aged 10 years or above
Exclusion
- • None
- Ribavirin PK/PD study
- Inclusion Criteria:
- Suspected or RT-PCR confirmed Lassa fever diagnosis
- Patient will receive ribavirin therapy
- Aged 10 years or above
Key Trial Info
Start Date :
November 26 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 15 2021
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT04285034
Start Date
November 26 2019
End Date
July 15 2021
Last Update
October 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Owo Federal Medical Centre
Owo, Ondo State, Nigeria, PMB 1053